Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07355062 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis
A Phase 3 study of Metabolic Acidosis and CKD, sponsored by Renibus Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
- 8
- Study locations
NCT07355062: Recruiting Phase 3 study of Metabolic Acidosis and CKD, sponsored by Renibus Therapeutics.
NCT07355062 is a Phase 3 study of Metabolic Acidosis and CKD that is actively recruiting participants, run by Renibus Therapeutics. The registered enrollment target is 150 participants, above the 64-participant average among 4 other Metabolic Acidosis trials with a reported enrollment target (134% higher). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07355062, a Phase 3 study of Metabolic Acidosis and CKD, is actively recruiting participants, sponsored by Renibus Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this 26 week study is is to evaluate the efficacy and safety of veverimer in treating adults with moderate-to-severe chronic kidney disease (CKD) and metabolic acidosis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Veverimer
Study Locations (8)
Florida
- Velocity Clinical Research - Edgewater
- Belkis Delgado MD PA - Miami Springs
California
- Academic Medical Research Institute - Los Angeles
Illinois
- Research by Design - Chicago
Kentucky
- Nephrology Associates of Kentuckiana - Louisville
New York
- New York-Presbyterian Queens - Fresh Meadows
North Carolina
- Brookview Hills Research Associates - Winston-Salem
Texas
- Clinical Advancement Center - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-01-13 |
| Est. Completion | 2027-06 |
| Phase | Phase 3 |
What NCT07355062 shows while recruiting
NCT07355062 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 64-participant average among 4 other Metabolic Acidosis trials with a reported enrollment target (134% higher).
The record links to 2 conditions, with Metabolic Acidosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07355062 lists 8 locations in 7 states (Florida, California, Illinois).
Frequently Asked Questions
What is clinical trial NCT07355062 about?
NCT07355062 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis". The purpose of this 26 week study is is to evaluate the efficacy and safety of veverimer in treating adults with moderate-to-severe chronic kidney disease (CKD) and metabolic acidosis.
What is the current status of trial NCT07355062?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2026-01-13. Estimated completion is 2027-06.
What conditions does trial NCT07355062 study?
This clinical trial studies the following conditions: Metabolic Acidosis, CKD.
What interventions are being tested in trial NCT07355062?
The interventions under investigation include: Placebo (DRUG), Veverimer (DRUG).
Who is sponsoring clinical trial NCT07355062?
This trial is sponsored by Renibus Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07355062 being conducted?
This trial has 8 study locations across California, Florida, Illinois, Kentucky, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metabolic Acidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
RECRUITING · Phase 2
-
Adding Urea to the Final Dialysis Fluid
RECRUITING · Phase 1
-
Effect of Alkali Therapy on Vascular and Graft Function in Kidney Transplant Recipients
RECRUITING · Phase 4
-
Bicarbonate Administration and Cognitive Function in Midlife and Older Adults With CKD
COMPLETED · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI